Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of GSK2586184, and the effect of food and gender…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GSK2586184 (GSK2586184)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED